Differences in the serum metabolome and lipidome identify potential biomarkers for seronegative rheumatoid arthritis versus psoriatic arthritis.
M Margarida Souto-CarneiroLilla TóthRouven BehnischKonstantin UrbachKarel D KlikaRui A CarvalhoHanns-Martin LorenzPublished in: Annals of the rheumatic diseases (2020)
PsA and negRA have distinct serum metabolomic and lipidomic signatures that can be used as biomarkers to discriminate between them. After validation in larger multiethnic cohorts this diagnostic model may become a valuable tool for a definite diagnosis of negRA or PsA patients.
Keyphrases
- prostate cancer
- rheumatoid arthritis
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- ejection fraction
- peritoneal dialysis
- prognostic factors
- genome wide
- disease activity
- gene expression
- systemic lupus erythematosus
- dna methylation
- patient reported outcomes
- ankylosing spondylitis
- idiopathic pulmonary fibrosis